Recent observations suggest that the serum neurofilament light chain (sNfL) can serve as a biomarker at the very early stages of MS (69) and the combination of NfL with other potential biomarkers in serum or CSF showed high MS prediction score (70). The gene discussed is NEFL; the disease is myeloid sarcoma.